Plus, rheumatology drug news from EULAR 2014
EULAR 2014: Non-Tumor Necrosis Factor Biologics Update
Clinical trials on rheumatology drugs, including sarilumab, show promise for patients with rheumatoid arthritis also taking methotrexate
EULAR 2014: Biosimilar Drug Production Raises Concerns
Rheumatology experts question biosimilars’ safety, efficacy given their complex production process
EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis
Latest findings on rheumatological drug therapies, including methotrexate for RA, tumor necrosis factor inhibitors for SpA
Long Delays for Appointments Underscore Need for More Rheumatologists
Patient access to rheumatologists a serious concern in rural and underserved U.S. communities
Is Shared Decision Making Possible in Rheumatology?
A rheumatologist voices skepticism that physicians, patients can arrive at mutually shared healthcare decisions
Walking Aids in Assessment of Rheumatology Patients
Rheumatologists can gain insight into patients’ state of health by watching them walk
7 Tools to Identify Depression
Why screening for depressive symptoms in patients with arthritis is needed
Rheumatology Drug Updates, Trials, Safety Data
An update on baricitinib, plus safety warnings on belimumab,
eszopiclone and zoledronic acid
Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis
Physicians at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco report on studies about JAK inhibitors as targeted immunomodulators and disease-modifying therapies in RA
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 74
- Next Page »